Disease/Infection News

RSS

Depressed seroconversion in immunocompromised COVID-19 vaccine recipients

Researchers from the University of Singapore have reviewed the data in post-vaccinated immunocompromised patients to examine the effectiveness of these vaccines in these patients.

5 Oct 2021

How accurate is COVID-19 modeling?

Researchers from the Burnet Institute in Melbourne have been using this to investigate how accurate COVID-19 modelling has been.

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Study suggests shingles vaccine reduces the risk for COVID-19

People who get the shingles vaccine may have a lower risk of being diagnosed and hospitalized with coronavirus disease 2019 (COVID-19), according to a new medRxiv* preprint study. In about 150,000 people over the age of 50, vaccination for shingles was associated with a 32% reduced risk of severe COVID-19 infection.

5 Oct 2021

Inflammatory molecules "trapped" inside micro clots may be the cause of Long COVID symptoms

New research indicates that an overload of various inflammatory molecules, literally "trapped" inside insoluble microscopic blood clots (micro clots), might be the cause of some of the lingering symptoms experienced by individuals with Long COVID.

5 Oct 2021

New study underscores the importance of improving COVID-19 vaccination rates worldwide

Two doses of Pfizer-BioNTech (BNT162b2) are 90% effective against COVID-19 hospitalizations for all variants, including delta, for at least six months, confirms a new study from Kaiser Permanente and Pfizer published in The Lancet.

5 Oct 2021

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

Researchers from the US recently characterized the scale and specificity of SARS-CoV-2 spike-reactive antibodies from 23 participants who received SARS-CoV-2 mRNA vaccines and 10 acutely infected health care workers. They found that primary mRNA vaccination and infection elicited S1- and S2-reactive antibodies, while secondary mRNA vaccination elicited mostly S1 antibodies.

4 Oct 2021

Is gout a risk factor for COVID-19?

A team of international scientists has recently determined the association between gout and risk of coronavirus disease 2019 (COVID-19) related death in a large cohort of patients. Their findings reveal that gout can significantly increase the risk of COVID-19 and related mortality, with women having a higher risk than men. The study is currently available on the medRxiv* preprint server.

4 Oct 2021

What makes SARS-CoV-2 variants more virulent?

Researchers in the Republic of Korea have conducted a study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – that could help to inform further studies investigating the increased virulence of variants of concern and interest.

4 Oct 2021

Scientists analyze if T-cell tests can be used to determine whether people had COVID-19

Can T-cell tests be used to determine whether people have had COVID-19? Scientists at Uppsala University and Karolinska Institutet have jointly analysed this issue under the aegis of the COMMUNITY study at Danderyd Hospital. Their study is published in the scientific journal PLOS ONE.

4 Oct 2021

Convalescent plasma is "futile" as COVID-19 treatment for critically ill patients, trial shows

In the earliest days of the COVID-19 pandemic, the medical community turned to a century-old treatment: Take blood from recovered patients and give it to the sick.

4 Oct 2021

Moderna's COVID-19 vaccine proves effective against multiple SARS-CoV-2 variants, including delta

Researchers in the United States have demonstrated the real-world effectiveness of Moderna’s mRNA-1273 vaccine at protecting against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and preventing hospitalization due to coronavirus disease 2019 (COVID-19).

4 Oct 2021

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.

4 Oct 2021

J&J vaccine prevents SARS-CoV-2-induced thrombosis and inflammation in hamsters

In a recent study, researchers performed bulk RNA-Seq transcriptomic profiling of lungs from vaccinated and unvaccinated hamsters with the Janssen vaccine.

4 Oct 2021

How durable is the immune response generated from the BNT162b2 vaccine?

In a recent study, researchers analyzed antibody responses to the homologous Wu strain and several other SARS-CoV-2 variants after BNT162b2 vaccination.

4 Oct 2021

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

A recent study assesses the serological and cellular responses to Pfizer’s BNT162b2 mRNA vaccine in people aged 80-96 years.

4 Oct 2021

Health-related quality of life of COVID-19 patients with long-COVID: Study

Researchers conducted a survey-based study and assessed the impact of long COVID on the health-related quality of life in Japanese COVID-19 patients.

4 Oct 2021

Using nasopharyngeal microbiota as early biomarker in patients with COVID-19

A new study aimed to analyze the nasopharyngeal microbiota of patients who were hospitalized with COVID-19.

4 Oct 2021

Elucidating the natural spillover theory on the SARS-CoV-2 emergence

To determine whether SARS-CoV-2 resulted from a natural spillover into humans, researchers discuss the veracity of early SARS-CoV-2 lineages.

4 Oct 2021

Post-COVID depressive symptoms respond well to antidepressants, study shows

The COVID pandemic has led to a significant increase in mental health problems. Now, in some good news, a pilot study has shown that depressed patients who have suffered from COVID respond better to standard antidepressants than do people who have not had COVID.

4 Oct 2021